Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics in inflammatory bowel disease.

Marie Pierik1, Paul Rutgeerts, Robert Vlietinck

  • 1Department of Gastro-enterology, University of Hospital Gasthuisberg, Leuven, Belgium. marieke.pierik@uz.kuleuven.ac.be

World Journal of Gastroenterology
|June 15, 2006
PubMed
Summary

Pharmacogenetics tailors drug treatments to individual genetic profiles for improved efficacy and safety in inflammatory bowel diseases (IBD). Currently, only TPMT gene variations impacting thiopurine drug toxicity are clinically applied in IBD treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: A20 controls intestinal homeostasis through cell-specific activities.

Nature communications·2025
Same author

Genome-wide association study meta-analysis of dizygotic twinning illuminates genetic regulation of female fecundity.

Human reproduction (Oxford, England)·2023
Same author

Fatigue and Physical Activity Patterns in Children With Inflammatory Bowel Disease.

Journal of pediatric gastroenterology and nutrition·2023
Same author

Analysis of Systemic Epigenetic Alterations in Inflammatory Bowel Disease: Defining Geographical, Genetic and Immune-Inflammatory influences on the Circulating Methylome.

Journal of Crohn's & colitis·2022
Same author

Histopathological Features in Colonic Biopsies at Diagnosis Predict Long-term Disease Course in Patients with Crohn's Disease.

Journal of Crohn's & colitis·2021
Same author

Disease Activity Patterns of Crohn's Disease in the First Ten Years After Diagnosis in the Population-based IBD South Limburg Cohort.

Journal of Crohn's & colitis·2020

Area of Science:

  • Pharmacogenetics and its application in gastrointestinal medicine.

Background:

  • Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), involve complex treatment regimens.
  • Variability in drug response and toxicity necessitates personalized medicine approaches.

Purpose of the Study:

  • To review gene variants influencing the efficacy and toxicity of common IBD drugs.
  • To discuss challenges in pharmacogenetic studies within the IBD population.
  • To highlight current clinical applications and future directions in IBD pharmacogenetics.

Main Methods:

  • Review of genetic polymorphisms affecting drug metabolism and response in IBD.
  • Analysis of drugs including sulfasalazine, mesalazine, azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate (MTX), glucocorticosteroids (CSs), and infliximab.

Related Experiment Videos

  • Discussion of methodological challenges in pharmacogenetic research for IBD.

    • Main Results:

    • Identified gene variants impacting efficacy or toxicity for several IBD medications.
    • The only clinically implemented pharmacogenetic finding in IBD is the association between thiopurine S-methyltransferase (TPMT) gene polymorphisms and hematological toxicity from thiopurine therapy.
    • Significant challenges exist in conducting robust pharmacogenetic studies in IBD.

    Conclusions:

    • Pharmacogenetics offers promise for optimizing IBD treatment, but clinical translation remains limited.
    • Standardized, well-characterized patient cohorts and objective response measures are crucial for future research.
    • Genomic data collection in clinical trials is essential for advancing pharmacogenetic understanding in IBD.